Document is current

Any future updates will be listed below

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

Crossref DOI link: https://doi.org/10.1186/s12967-017-1251-3

Published Online: 2017-06-29

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark